Matching halt.
1 Like
Jeg føler meg supersmart som solgte på fredag. 
2 Likes
Uff! … føler med deg 
Stor tabbe av Storebrand vekst her?
1 Like
Ja, men salget deres helt ned til 5 skapte kjøpsanledningen denne gangen. Synes hele salget og måten det skjedde på da de først skulle selge var merkelig. Og de er med som garantisk på 7 kr nå…
1 Like
Nå har ikke jeg RT, og får først nå se hvor dramatisk oppgang det har vært i dag. Har dette kun med t-rettene til 7kr å gjøre, eller er det flere grunner? Kan noen belyse litt…
Forresten. Matching halt ends.
PCIB har vært grovt underpriset i lang tid sammenlignet med f.eks. NANO. Nå har markedet oppdaget caset, kanskje gjorde de det før, men ville vente til emisjonsmld kom. Det er vel ikke værre enn det?
Og forskningsresultatene så langt er fantastisk gode for gallegangskreft sammenlignet med den behandling pasientene får i dag.
Selskapet har vært priset utrolig lavt pga en kombinasjon av emisjonsfrykt og at man ventet på resultater fra kliniske studier.
Nå kom det først resultater som er så sterke at de vil være helt sensasjonelle om de lar seg reprodusere på et større antall pasienter, og vi har endt opp med en emisjon som er alt annet enn en kriseemisjon på 2-3 tallet slik det var fryktet.
Når man da kombinerer dette med en kokhet hype rundt biotech pga alle selskapene i Oslo Cancer Cluster som gjør det sterkt for tiden, så blir det tydeligvis eksplosivt.
1 Like
Nei, det er vel kanskje ikke det…
Det har jeg forsåvidt skjønt etter å ha lest meg opp litt, samt fulgt med på hva som er skrevet her inne. Nå sitter jeg og dunker meg selv i pannen fordi jeg ikke fikk kommet meg inn på fredag.
Som du skriver Savepig, så tror jeg det også er en synergieffekt av at f.eks. Nano har hatt en ganske vill kursoppgang i det siste.
hehe, takk. Er surt, men hadde en fin gevinst uansett, så skal ikke gråte/bli grådig 
1 Like
Jeg selger ikke, kall meg gjerne grådig 
2 Likes
Hvem er det som selger via NEO mon tro?. nettosolgte bra på fredag og selger ca. 150k i dag. Dominerer totalt på nettosalg.
Bet meg merke i dette selv.
Sikkert den samme julenissen som nettosolgte hundretusener NANO på 26 opp til 35 før de var tom.
Kjøpssignal imo.
Disse resultatene : mener det bare er testet på 3 pasienter? Tar jeg helt feil?
Litt flere enn det heldigvis. 
LB06 - PHASE I STUDY WITH PHOTOCHEMICAL INTERNALISATION (PCI) – A NOVEL TECHNOLOGY FOR TREATMENT OF PERIHILAR CHOLANGIOCARCINOMA
R. Sturgess,D. Palmer,J. Trojan,A. Hoffmeister,B. Neu,S. Kasper,A. Dechêne,C. Jürgensen,J. Schirra,R. Jakobs,A. Høgset,L. Finnesand
Introduction
Despite the advancement of new surgical and chemotherapeutic treatments for patients with perihilar cholangiocarcinoma (CCA), the prognosis for patients is still poor. PCI is a novel therapeutic technology, which may improve the treatment options for this patient group.
Aims & Methods
PCI can enhance the therapeutic effect of a variety of molecules, including several commonly used cytotoxic drugs. Fimaporfin (TPCS2a) is a proprietary photosensitiser that is used to induce PCI. It is designed to localise to endosomal membranes and induce endosomal disruption upon light activation. Many cancer drugs and other molecules of therapeutic interest may end up entrapped in endosomes. PCI can induce the release of such molecules from the endosomes, thereby enabling them to reach their therapeutic target in the cell cytosol or nucleus. Based on positive preclinical results for PCI and gemcitabine and promising results from the first in man study with PCI in patients with various solid tumors1,2, it was decided to start a phase I/II study to investigate the effect of PCI with gemcitabine in patients with advanced inoperable perhilar CCA. The aim of this study was to establish the safety and tolerability of PCI with gemcitabine followed by standard systemic chemotherapy. The study was conducted at several centers in Germany, Norway and UK.
Local radiological assessments were performed in phase I. A retrospective independent radiological evaluation was performed for the last two dose cohorts, to verify promising early signs of efficacy.
Results
A total of 16 patients were treated in the dose escalating Phase I part of this study. Four different dose cohorts were tested. The last patient completed the 6 months follow-up period in September 2016. Of the 16 patients treated, 11 completed the 8 cycles of combination therapy, and 5 patients were early withdrawals. No patients expired while still on study. The treatment was well tolerated with no DLTs, and no serious safety concerns were raised. In the last two dose cohorts, independent radiological evaluation showed that 7 out of 8 patients had evaluable tumor, and four of these showed an objective tumor response at six months, including two complete responses.
Conclusion
The patient number in this clinical study is small, but the results indicate high durable objective tumor response rates. The early signs of efficacy using PCI treatment with fimaporfin and gemcitabine are encouraging.
References
-
Sultan et al (2016) Disulfonated tetraphenyl chlorin (TPCS2a)-induced photochemical internalisation of bleomycin in patients with solid malignancies: a phase 1, dose-escalation, first-in-man trial. Lancet Oncology 17(9): p1217–1229
-
Madsen (2016) Photochemical internalisation for solid malignancies. Lancet Oncology Volume 17(9): p1173–1174
2 Likes
Se der ja, Takk @Savepig - men den vaksinedelen har bare 3 pasienter, korrekt? Merker jeg må sette meg mer inn i dette caset. Ikke like enkelt som Nano som bare har 1 produkt å forholde seg til
22.11.2016 08:00:29: PCI Biotech: Third quarter 2016 results
Oslo, 22 November 2016 - Please find enclosed the financial report for third quarter 2016 for PCI Biotech Holding ASA.
Highlights
fimaChem
Completed Phase I study in bile duct cancer, with early promising results confirmed at central expert review
Oral presentation of the Phase I results as late-breaking news at United European Gastro Week 2016
Granted Orphan Drug Designation of fimaporfin for treatment of bile duct cancer in EU
Lancet Oncology publication of the fimaporfin (Amphinex) first-in-man Phase I study, with independent expert commentary
fimaVacc
Initiated clinical validation of the vaccination technology - a major development milestone
fimaNAc
Research collaboration agreement with BioNTech signed
Financials
The Company proposes to carry out a fully underwritten rights issue of NOK 70 million at a subscription price of NOK 7 per share
CEO, Per Walday, comments:
“We have reached several important milestones for the fimaChem program in 2016. On the back of this progress, we were very pleased to recently announce a fully underwritten rights issue of NOK 70 million. The funding will enable the company to complete the initiated interactions with regulatory authorities to determine the best approach to marketing approval. In addition, the rights issue will fully fund translation of our fimaVacc technology into man. Improving immunogenicity of vaccine candidates is a main priority in the immunotherapy industry and we believe that the fimaVacc technology may play an important part in solving this challenge. We are also facing increased interest in our fimaNAc technology and we look forward to explore synergies with BioNTech’s pioneering disruptive technologies”.
About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead fimaChem programme consists of a Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
For more information visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 9400 5757
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
PCI Biotech Q3 2016 Report
2 Likes
Er litt ny til aksjehandel, og har noen spørsmål. Ser at PCI skal utføre emisjon, og kursen gikk vel opp for at den fastsatte prisen ble på 7kr og ikke lavere. Men hvordan vil emisjonen påvirke aksjekursen? Jeg tenker å satse på PCI (ikke mye), men vil det være gunstig å vente til etter emisjonen eller før?
2 Likes
Når kommer rettene da `? Og hvilken dato er det du må ha aksjer får og få krav på retter ? Noen pleeeease ?